Digital Bio Pharm
DigitalBioPharm ltd is a R&D company, which unites several IT and medicinal chemistry professionals worldwide. Our main philosophy is based on IT-solutions usage. We believe that effectiveness of such approaches will evolve over time and we are working hard on making this real. There are many effective and robust early in silico drug discovery algorithms now. If used properly according the purposes these algorithms can provide competitive solutions, additional to wet-lab experiments. Such solutions may have a positive impacts of time and costs of the early drug discovery which is crucial for the competitive advantages of our clients and research partners. We also provide solutions in the fields of biomedical software development. GPGPU programming and distributed grid and cloud computing. Our philosophy involves development and usage of open source software for purposes of drug discovery and biotechnology. The main benefits for our potential partners we see in the flexible conditions of collaboration and optimal research planning for each individual project. We can provide services on collaborative basis for the intellectual property share.
Parkinson's disease is second most common neurodegenerative disease. Treating Parkinson's disease is based on levodopa and two alternatives dopamine agonist (DA) and monoanime oxidase type B inhibitors (MAOBI). Prolonged use of levodopa can lead to appearance of involuntary muscle spasms and movement functions. Beside good results with DA and MAOBI, still the most widely used drug for the treatment of the Parkinson's disease is levodopa.
AFFiRiS AG from Viena, Austria have announced data of compound AD04 from phase II study in Alzheimer's patients. The compound AD04 has shown significant results in cognitive/functional outcome and the volume of the hippocampus during 18 months. The compound AD04 also shown an impact on behavioral and quality of life outcomes. Depend on dosage and formulation compound AD02, 24-31% of the patients showed cognitive and functional improvement and stabilization. During 18 months Hippocampusvolume could not be detected.
Patients with multiple myeloma relapse and develop resistance to a treatment. That's why new therapies are crucial to fight the disease and increase survival rate of patients with multiple myeloma. Novartis presented results of LBH589 (panobiostat) in combinations with bortezomib and dexamethasone showing increases of 37% in progression-free survival in comparison to the treatment of same regimen with placebo in patients with relapsed or relapsed and refractory multiple myeloma.